Stockreport

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

LAVA Therapeutics N.V. - Ordinary Shares  (LVTX) 
PDF LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical d [Read more]